Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,891 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: therapeutic insulin Clear all
Enrolling by invitation Not applicable Interventional

Pilot RCT: FQHC Intervention for Uptake of CGM in Low-Income Adults With T1D

NCT06487962
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CGM Intervention, SMBG Control Condition
Device · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Middletown, Connecticut • Vero Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-Loop Glucagon Administration For Hypoglycemia Treatment

NCT02181127
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon-only Bionic Pancreas
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 20, 2026, 6:15 AM EDT
Terminated Not applicable Interventional Results available

A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure

NCT05904769
View directory record Official record
Conditions
Diabetes
Interventions
LIFELEAF Smartwatch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

NCT02523131
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM, Medtronic insulin pump 640G
Device
Lead sponsor
University of Cambridge
Other
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

NCT01308437
View directory record Official record
Conditions
Type I Diabetes
Interventions
Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 20, 2026, 6:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance

NCT03509441
View directory record Official record
Conditions
Cardiomyopathies, Insulin Resistance, Non-ischemic Cardiomyopathy, Cardiac Fibrosis, Diabetes
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 20, 2026, 6:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Insulin Variance Throughout the Day

NCT01546545
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional

The Measurement of Insulin Resistance in Peritoneal Dialysis Patients

NCT01119196
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Icodextrin dialysate
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 20, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional

Diazoxide Suppression Test P&F Study

NCT06606327
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity
Interventions
Diazoxide, 3 mg/kg per dose
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

Detemir: Role in Type 1 Diabetes

NCT00564395
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

NCT01326533
View directory record Official record
Conditions
Pre-diabetes
Interventions
hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 20, 2026, 6:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sarcopenic Obesity in the Elderly

NCT06083909
View directory record Official record
Conditions
Sarcopenic Obesity, Diabetes
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
65 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 20, 2026, 6:15 AM EDT
Recruiting Not applicable Interventional

Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial

NCT06274749
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Urolithin A, Placebo
Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Metabolic Impact of Fructose Restriction in Obese Children

NCT01200043
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
fructose restriction diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

NCT05803421
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Interventions
Orforglipron, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
173
States / cities
Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)

NCT03064906
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulet AP (artificial pancreas) System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Palo Alto, California • Walnut Creek, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Results available

OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

NCT01182493
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Pump (Medtronic Minimed Paradigm® VEO)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Albany, New York • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

NCT00304993
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance
Interventions
fenofibrate, niacin, rosiglitazone
Drug
Lead sponsor
Foundation Research, Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2006 · Synced Sep 20, 2026, 6:15 AM EDT
Not listed Phase 2 Interventional

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

NCT03784287
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIB, MPS III B
Interventions
AX 250
Drug
Lead sponsor
Allievex Corporation
Industry
Eligibility
0 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Oakland, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 20, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Intra-Arterial Microdosing: Proof-of-Concept in Humans

NCT02304211
View directory record Official record
Conditions
Healthy
Interventions
Insulin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 20, 2026, 6:15 AM EDT